IP Library Granted Patent US 12,161,607
Granted Patent B2
US 12,161,607 · App. 17/231,625 · Granted Dec 10, 2024

Combination of cannabinoids in the treatment of leukemia

Inventors: Stephen Wright (Cambridge, GB); Wai Liu (London, GB); Katherine Scott (London, GB); Angus Dalgleish (London, GB)
Assignee: Jazz Pharmaceuticals Research UK Limited
A61K31/05A61K31/352A61P35/02A61K31/475A61K31/7068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,161,607
App. No.
17/231,625
Granted
Dec 10, 2024
Kind
B2
Abstract

The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract of Cannabis such that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of Cannabis , wherein the CBD or THC are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.

Claims (16)

1. A method of treating leukemia comprising administering (i) cannabidiol (CBD) and tetrahydrocannabinol (THC), wherein CBD and THC are administered in a ratio of from 2:1 to 1:2 CBD:THC and (ii) a chemotherapeutic drug to a subject in need thereof, wherein the leukemia is acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).

2. The method of treating leukemia according to claim 1 , wherein the CBD and the chemotherapeutic drug are administered separately.

3. The method of treating leukemia according to claim 1 , wherein the leukemia is acute lymphoblastic leukemia (ALL).

4. The method of treating leukemia according to claim 1 , wherein the leukemia is acute myeloid leukemia (AML).

5. The method of treating leukemia according to claim 1 , wherein the leukemia is a childhood leukemia.

6. The method of treating leukaemia according to claim 1 , wherein the CBD is present in the form of a Cannabis plant extract.

7. The method of treating leukaemia according to claim 6 , wherein the CBD is present as a highly purified extract of Cannabis which comprises at least 98% (w/w) of CBD.

8. The method of treating leukaemia according to claim 1 , wherein the CBD is present as a synthetic compound.

9. The method of treating leukemia according to claim 1 , comprising administering CBD in a dose of from 0.1 to 100 mg/kg/day.

10. The method of treating leukemia according to claim 1 , wherein the chemotherapeutic drug is cytarabine.

11. The method of treating leukemia according to claim 10 , wherein the chemotherapeutic drug is vincristine and leukemia is acute lymphoblastic leukemia.

12. The method of treating leukemia according to claim 10 , wherein the chemotherapeutic drug is cytarabine and the type of leukemia is acute myeloid leukemia.

13. The method of treating leukemia according to claim 2 , comprising administering the CBD and the chemotherapeutic drug sequentially.

14. The method of treating leukemia according to claim 2 , comprising administering the CBD and the chemotherapeutic drug simultaneously.

15. The method of treating leukemia according to claim 1 , comprising administering CBD and THC in a ratio of 1:1 CBD:THC.

16. The method of treating leukemia according to claim 1 , wherein the chemotherapeutic drug is vincristine.

Assignments (3)
CHANGE OF NAME Recorded Oct 14, 2024
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 068889/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: WRIGHT, STEPHEN; LIU, WAI; SCOTT, KATHERINE; DALGLEISH, ANGUS
To: GW RESEARCH LIMITED
Reel/Frame 061405/0492 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
Priority Claims (1)
GB 1703115 · Feb 27, 2017 · national
Continuity (2)
Continuation 16488821
Related Publication 20210308072A1 · Oct 7, 2021
Cited By (3)
US 12,427,160 US 12,569,505 US 12,661,365